Insight

Yüksel Ürün: Top Advances of the Year in Perioperative Therapy for Lung Cancer

Photo from Yüksel Ürün/X

May 18, 2024, 10:20

Yüksel Ürün: Top Advances of the Year in Perioperative Therapy for Lung Cancer

Yüksel Ürün shared on X: .

“Top Advances of the Year: Perioperative Therapy for Lung Cancer

In 2023, perioperative immune checkpoint inhibitors (ICIs) became a game-changer for early-stage non-small cell lung cancer (NSCLC)
Despite these advances, optimizing patient selection and biomarker use remains a challenge”

Read further.
Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes.

His dedication to patient care and research inspires positive change in the medical field.

Ankara University School of Medicine cancer Immune checkpoint inhibitors (ICIs) Lung cancer non small cell lung cancer NSCLC OncoDaily Oncology Perioperative Therapy Top Advances of the Year Yüksel Ürün

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage